Cargando…
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
Triple-negative breast cancer (TNBC) is associated with high recurrence rates, high incidence of distant metastases, and poor overall survival (OS). Taxane and anthracycline-containing chemotherapy (CT) is currently the main systemic treatment option for TNBC, while platinum-based chemotherapy showe...
Autores principales: | Ferrari, Paola, Scatena, Cristian, Ghilli, Matteo, Bargagna, Irene, Lorenzini, Giulia, Nicolini, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836182/ https://www.ncbi.nlm.nih.gov/pubmed/35163586 http://dx.doi.org/10.3390/ijms23031665 |
Ejemplares similares
-
Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015) -
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017) -
Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023) -
Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022) -
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
por: Petrosyan, Varduhi, et al.
Publicado: (2022)